These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11399967)

  • 1. Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients.
    Zöllner B; Feucht HH; Schröter M; Schäfer P; Plettenberg A; Stoehr A; Laufs R
    AIDS; 2001 May; 15(7):935-6. PubMed ID: 11399967
    [No Abstract]   [Full Text] [Related]  

  • 2. Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.
    Depatureaux A; Charpentier C; Collin G; Leoz M; Descamps D; Vessière A; Damond F; Rousset D; Brun-Vézinet F; Plantier JC
    Antimicrob Agents Chemother; 2010 Sep; 54(9):4016-9. PubMed ID: 20547806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains.
    Roman F; Gonzalez D; Lambert C; Deroo S; Fischer A; Baurith T; Staub T; Boulmé R; Arendt V; Schneider F; Hemmer R; Schmit JC
    J Acquir Immune Defic Syndr; 2003 Jun; 33(2):134-9. PubMed ID: 12794544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change in HIV-1 DNA tropism despite virological success in patients receiving an enfuvirtide-based regimen.
    Charpentier C; Joly V; Ghosn J; Yeni P; Raffi F; Descamps D; Morand-Joubert L
    J Antimicrob Chemother; 2014 Sep; 69(9):2588-90. PubMed ID: 24816213
    [No Abstract]   [Full Text] [Related]  

  • 5. Virological fitness of HIV in patients with resistance to enfuvirtide.
    Chibo D; Roth N; Roulet V; Skrabal K; Gooey M; Carolan L; Nicholls J; Papadakis A; Birch C
    AIDS; 2007 Sep; 21(14):1974-7. PubMed ID: 17721108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enfuvirtide, an HIV-1 fusion inhibitor.
    Jenny-Avital ER
    N Engl J Med; 2003 Oct; 349(18):1770-1; author reply 1770-1. PubMed ID: 14593994
    [No Abstract]   [Full Text] [Related]  

  • 7. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
    Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR
    J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enfuvirtide, an HIV-1 fusion inhibitor.
    Carr A
    N Engl J Med; 2003 Oct; 349(18):1770-1; author reply 1770-1. PubMed ID: 14585947
    [No Abstract]   [Full Text] [Related]  

  • 9. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3253-9. PubMed ID: 15328081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
    N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
    Wei X; Decker JM; Liu H; Zhang Z; Arani RB; Kilby JM; Saag MS; Wu X; Shaw GM; Kappes JC
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1896-905. PubMed ID: 12019106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
    Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
    N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HIV-1 fusion inhibitor improves treatment in HIV-1-resistant patients].
    Blasko M
    Dtsch Med Wochenschr; 2003 May; 128(19):1032. PubMed ID: 12774800
    [No Abstract]   [Full Text] [Related]  

  • 15. Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough.
    Meyohas MC; Lacombe K; Carbonne B; Morand-Joubert L; Girard PM
    AIDS; 2004 Sep; 18(14):1966-8. PubMed ID: 15353987
    [No Abstract]   [Full Text] [Related]  

  • 16. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Strategies for combating resistances in HIV therapy--an exemplifying case].
    Stoehr A
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056
    [No Abstract]   [Full Text] [Related]  

  • 18. Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?
    Morse C; Maldarelli F
    J Infect Dis; 2007 Feb; 195(3):318-21. PubMed ID: 17205468
    [No Abstract]   [Full Text] [Related]  

  • 19. Functional characteristics of the natural polymorphisms of HIV-1 gp41 in HIV-1 isolates from enfuvirtide-naïve Korean patients.
    Shin Y; Yoon CH; Yang HJ; Lim H; Choi BS; Kim SS; Kang C
    Arch Virol; 2016 Jun; 161(6):1547-57. PubMed ID: 26997611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.
    Marcial M; Lu J; Deeks SG; Ziermann R; Kuritzkes DR
    J Clin Microbiol; 2006 Sep; 44(9):3384-7. PubMed ID: 16954280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.